Strategies for balancing the efficacy and immune-related adverse events in personalized immunotherapy for advanced lung cancer
WANG Li-qiang
XIE Xiao-hong
LIN Xin-qing
ZHOU Cheng-zhi
Abstract：Immune checkpoint inhibitors(ICIs)have significantly increased the efficacy of treatment for advanced lung cancer,but at the same time,they also increase the risks of immune-related adverse events(irAEs).The occurrence of irAEs is closely related to the efficacy,but improper management may severely affect the prognosis and quality of life of the patients.In individualized immunotherapy for advanced lung cancer,it is possible to achieve dynamic balance between treatment efficacy and safety through multidimensional risk assessments,multi-omics data-integrated prediction,refined staging management,and dynamic monitoring and warning.Multidisciplinary team collaboration and patient education are very important,and telemedical technologies are of some value in the long-term follow-up and immunotherapeutic rechallenge.In the future,the application of artificial intelligence technologies is promising in further enhancing precision and safety of immunotherapy.
Keywords：advanced lung cancerpersonalized immunotherapyimmune checkpoint inhibitorsimmune-related adverse events
Publication Date：2025-06-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 471-476 )